BioPharma Dive 8. Dez. 2025 Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
BioPharma Dive 26. Nov. 2025 Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3